Abstract
Botulinum toxin type A (Botox®) interferes with acetylcholine release from nerve terminals causing temporary paralysis of the injected muscles. The pioneering work of Scott1 over 25 years ago was for strabismus. In 1989 it was approved for blepharospasm, hemifacial spasm, torticollis, and strabismus. Since then it has been approved for cosmetic treatment of the glabellar furrows and axillary hyperhydrosis. Botox has become the number one cosmetic procedure and is widely used to treat rhytids of the glabella, forehead, eyelids; nasal; cervical; and perioral areas. Offlabel oculofacial uses include: hyperkinetic wrinkles of the face; hyperlacrimation; eyelid retraction; spastic entropion; blepharoptosis; migraine/stress headaches; and improving symmetry for facial palsy.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReference
Scott AB. Development of botulinum toxin therapy. Dermctol Clin 2004;22(2):131–133.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2008 Springer Science+Business Media, LLC
About this chapter
Cite this chapter
Burroughs, J.R., Anderson, R.L. (2008). Introduction to Botox. In: Hartstein, M.E., Holds, J.B., Massry, G.G. (eds) Pearls and Pitfalls in Cosmetic Oculoplastic Surgery. Springer, New York, NY. https://doi.org/10.1007/978-0-387-69007-0_89
Download citation
DOI: https://doi.org/10.1007/978-0-387-69007-0_89
Publisher Name: Springer, New York, NY
Print ISBN: 978-0-387-25389-3
Online ISBN: 978-0-387-69007-0
eBook Packages: MedicineMedicine (R0)